Navigation Links
BioTech Holdings Announces First Clinical Use of Microbiome Optimized Autologous Stem Cells
Date:7/7/2017

SAN DIEGO, July 7, 2017 /PRNewswire/ -- BioTech Holdings announced today clinical safety data on 3 patients suffering from critical limb ischemia treated with the Company's Procell microbiome-optimized personalized stem cell product. 

In the investigator initiated pilot study, patients with diabetes associated circulation deficit in the legs (critical limb ischemia), who failed previous treatments were administered their own bone marrow derived stem cells that were treated with the Company's proprietary microbiome-derived compounds. 

No treatment associated adverse reactions were observed and patients were followed-up for 3 months.  Furthermore, 2 of the 3 patients had documented improvement in leg circulation and healing of previously unhealing ulcers.

"It is well known that the microbiome controls many aspects of human health and disease ranging from obesity, to autoimmunity, to even neurological function," said Thomas E Ichim, Ph.D, President and CEO of Biotech Holdings. "We are fortunate to have filed intellectual property on application of probiotics and microbiome manipulation to stem cells more than a year ago1.  The current study supports our forward movement of our ProCell product to formal clinical trials."

The Company's product, Procell, comprises of bone marrow stem cells from the same patient, that are treated with factors generated by the microbiome of healthy patients. The key ingredient that the company has identified as secreted by the microbiome which augments stem cell activity is already approved by the FDA for other indications. Accordingly, the company believes it is eligible for accelerated FDA registration pathways, including the 505b2 pathway.

The Company intends to develop the indication of critical limb ischemia as its first condition. Patients with this conditions have a major amputation rate as high as 40% at 6 months and a mortality rate of 20% to 25% in the first year after presentation. Critical limb ischemia represents a market of approximately 10 billion dollar per year2.

Contacts

Thomas E Ichim, Ph.D
President and Chief Executive Officer
BioTech Holdings
9255 Towne Centre Drive, #450
San Diego, CA 92121
167146@email4pr.com 
858 353 4303
Twitter: @biotechholdings

1 http://www.prnewswire.com/news-releases/biotech-holdings-announces-positive-preclinical-results-on-procell-probiotic-cell-therapy-for-critical-limb-ischemia-300278136.html

2 http://www.pluristem.com/wp-content/uploads/2016/04/Pluristem-January-2017.pdf

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/biotech-holdings-announces-first-clinical-use-of-microbiome-optimized-autologous-stem-cells-300484814.html


'/>"/>
SOURCE Biotech Holdings
Copyright©2017 PR Newswire.
All rights reserved


Related biology technology :

1. Founders of Philadelphia Biotech Enterin Inc. Discover Link Between Upper GI Tract Infections and Parkinsons Disease
2. Kibow Biotech Inc. (Buzz of Bio Winner, 2014) Receives US Patent for Gout/Hyperuricemia Product Formulation Based on Modulation of the Gut Microbiome With Probiotics and Prebiotics
3. Sentien Biotechnologies, Inc. Announces Open Enrollment in Phase 1/2 Trial of SBI-101 for Patients with Acute Kidney Injury
4. Greater Gainesville Region Advances as Florida’s Leading Location for Biotech Incubation and Technology Transfer
5. Pathway for Veterans into the Biotech Industry
6. UConn Innovation Fund Provides First Round Funding to Three Biotech Startups
7. Biotech Stocks Under Scanner -- Biostage, Keryx Biopharma, Kite Pharma, and ZIOPHARM Oncology
8. Research Reports Initiation on Biotech Stocks -- Tesaro, Alnylam Pharma, Corbus Pharma, and Inovio Pharma
9. Superior Controls and Banks Integration Group Merge, Creating Industry-Leading Biotech System Integration Company
10. iPath Media and DoyleCreek Strategic Communications Join Forces to Offer New Marketing Services to Pharmaceutical and Biotech Companies
11. Maxwell Biotech Venture Funds Portfolio Company Hepatera LLC Announces Completion of Recruitment for Phase 2b Clinical Trials of Myrcludex B in Chronic Hepatitis Delta
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/12/2017)... (PRWEB) , ... October 12, 2017 , ... ... in Vilnius, Lithuania, announced today that they have entered into a multiyear collaboration ... to provide CRISPR researchers with additional tools for gene editing across all applications. ...
(Date:10/11/2017)... ... October 11, 2017 , ... ... President Andi Purple announced Dr. Suneel I. Sheikh, the co-founder, CEO and chief ... ), Inc. has been selected for membership in ARCS Alumni Hall of ...
(Date:10/11/2017)... INDIANAPOLIS , Oct. 11, 2017  VMS BioMarketing, a ... of a nationwide oncology Clinical Nurse Educator (CNE) network, which ... growing need for communication among health care professionals to enhance ... physicians, nurses, office staff, and other health care professionals to ... for breast cancer. ...
(Date:10/10/2017)... DIEGO, CALIF. (PRWEB) , ... October 10, 2017 , ... ... as part of its corporate rebranding initiative announced today. The bold new look ... its reach, as the company moves into a significant growth period. , It will ...
Breaking Biology Technology:
(Date:3/29/2017)... 2017  higi, the health IT company that operates ... America , today announced a Series B investment ... EveryMove. The new investment and acquisition accelerates higi,s strategy ... transform population health activities through the collection and workflow ... higi collects and secures data today on behalf of ...
(Date:3/24/2017)... 2017 The Controller General of Immigration from Maldives ... Algeen have received the prestigious international IAIR Award for the most ... Reading ... Maldives ... Abdulla Algeen (small picture on the right) have received the IAIR award ...
(Date:3/23/2017)... Research and Markets has announced the addition of the "Global ... 2025" report to their offering. ... The Global Vehicle Anti-Theft System Market is ... next decade to reach approximately $14.21 billion by 2025. ... all the given segments on global as well as regional levels ...
Breaking Biology News(10 mins):